Authors: van Lemmen M A et al.
Anesthesiology, February 05, 2026, 10.1097/ALN.0000000000005931
This prospective crossover trial evaluated how effectively intranasal naloxone reverses opioid-induced respiratory depression caused by potent synthetic opioids. Because current overdose deaths are frequently related to high-affinity opioids such as fentanyl and its analogs, understanding the performance of commonly used intranasal naloxone formulations is increasingly important.
The investigators studied 30 volunteers divided into two groups: 12 opioid-naïve individuals and 18 self-reported daily opioid users. Daily users reported a wide range of opioid intake, with a median morphine milligram equivalent of 291 mg/day. Participants received continuous infusions of fentanyl or sufentanil to induce moderate respiratory depression, defined as a 30–40% reduction in minute ventilation. Sufentanil was included because of its higher opioid receptor affinity compared with fentanyl, allowing researchers to evaluate whether stronger receptor binding alters naloxone’s effectiveness.
Once steady-state respiratory depression was achieved, participants received a single 4 mg intranasal naloxone dose (Narcan®). The primary endpoints were the time required to restore ventilation and the time required to normalize elevated end-tidal carbon dioxide.
Naloxone rapidly restored minute ventilation in both opioid-naïve participants and daily opioid users. Ventilatory recovery typically occurred within 2 to 4 minutes after intranasal administration, demonstrating that the nasal formulation can quickly reverse opioid-induced suppression of breathing even in individuals exposed to potent opioids.
However, recovery of carbon dioxide clearance occurred more slowly and was less consistent. End-tidal CO₂ normalization required approximately 11 to 17 minutes. In the sufentanil experiments, full carbon dioxide recovery occurred in only a subset of participants: eight opioid-naïve individuals and ten daily opioid users. This finding suggests that while naloxone may rapidly stimulate breathing, ventilation may initially remain insufficient to fully correct hypercapnia.
Pharmacodynamic analysis showed extremely rapid onset of naloxone’s ventilatory effects. The blood-to-effect-site equilibration half-life for ventilatory recovery was estimated to be approximately 0 to 1 minute. In contrast, the equilibration half-life for CO₂ normalization ranged from 2 to 11 minutes. These findings illustrate that different physiologic endpoints of respiratory recovery respond at different rates following naloxone administration.
The study also highlighted challenges when reversing opioids in chronic users. Seven of the eighteen daily opioid users withdrew from the study after their first session due to withdrawal symptoms triggered by naloxone. This observation reflects a known limitation of naloxone reversal: rapid antagonism of opioid receptors can precipitate acute withdrawal in opioid-dependent individuals.
The authors note several important limitations. The study used controlled continuous opioid infusions rather than real-world overdose conditions, where individuals may receive massive doses or mixtures of opioids. Additionally, only moderate respiratory depression was induced. Severe overdose conditions, especially involving extremely potent opioids such as carfentanil, may require higher or repeated naloxone dosing.
Overall, the findings confirm that intranasal naloxone provides rapid reversal of opioid-induced respiratory depression but also demonstrate that physiologic recovery is not always complete or immediate. While ventilation improves quickly, normalization of carbon dioxide elimination may lag behind, particularly when high-affinity opioids such as sufentanil are involved. These findings support the continued use of intranasal naloxone in overdose treatment but also highlight the need for optimized dosing strategies and possibly improved antagonist formulations as synthetic opioids become more potent.
What You Should Know
Intranasal naloxone rapidly restored ventilation within minutes in both opioid-naïve individuals and chronic opioid users.
Recovery of carbon dioxide clearance was slower and sometimes incomplete, especially with high-affinity opioids like sufentanil.
These results suggest that breathing may resume quickly after naloxone but may initially remain physiologically inadequate.
Opioid-dependent participants frequently experienced withdrawal symptoms after naloxone administration.
The study supports the continued use of intranasal naloxone but indicates that higher or repeated dosing strategies may be required for potent synthetic opioids.
Key Points
A single 4 mg intranasal naloxone dose reversed fentanyl- and sufentanil-induced respiratory depression within 2 to 4 minutes.
Ventilatory recovery occurred faster than normalization of end-tidal carbon dioxide.
High-affinity opioids such as sufentanil produced slower or incomplete carbon dioxide recovery.
Blood-to-effect-site equilibration for ventilatory recovery was extremely rapid (approximately 0–1 minute).
Opioid-dependent participants frequently experienced withdrawal symptoms following naloxone reversal.
Further research is needed to determine optimal naloxone dosing strategies for modern synthetic opioid overdoses.
Thank you to Anesthesiology for allowing us to summarize this article.